MedDRA preferred term

Malignant neoplasm progression: adverse event reports recording this term

100,310 reports to FDA record it, 2004–2026; 0.5% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

100,310
reports recording the term: 0.5% of all reports; 8,084
reports, 12 months to June 2026: 6,944 in the 12 months before; 97.8%
marked serious by the reporter: 57.4% across all reports; 38.1%
record death among outcomes, as reported: 9.1% across all reports

"Malignant neoplasm progression" is a MedDRA preferred term recorded in 100,310 adverse event reports received by FDA, 0.5% of the database, from January 2004 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.

8,084 reports recorded it in the 12 months to June 2026, up 16% from 6,944 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 97.8% are marked serious, 38.1% include death among the outcomes and 26% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Keytruda, Nivolumab and Carboplatin. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Keytruda	Programmed death Receptor-1 blocking antibody	8,783	13.8%
Nivolumab	Programmed death Receptor-1 blocking antibody	5,094	11.1%
Carboplatin	Platinum-based drug	4,906	4.8%
Opdivo	Programmed death Receptor-1 blocking antibody	4,542	9.7%
Xtandi	Androgen receptor inhibitor	4,434	10.1%
Paclitaxel	Microtubule inhibitor	3,125	4.5%
Letrozole	Aromatase inhibitor	3,124	11.2%
Afinitor	Kinase inhibitor	3,048	9.9%
Cabometyx	Kinase inhibitor	2,937	7%
Pembrolizumab	Programmed death Receptor-1 blocking antibody	2,654	8.6%
Cyclophosphamide	Alkylating drug	2,584	1.8%
Cisplatin	Platinum-based drug	2,484	3.9%
Capecitabine	Nucleoside metabolic inhibitor	2,434	4.7%
Fulvestrant	Estrogen receptor antagonist	2,422	20.5%
Docetaxel	Microtubule inhibitor	2,262	3.8%
Yervoy	CTLA-4-directed blocking antibody	2,032	9.2%
Tagrisso	Kinase inhibitor	1,924	8.3%
Lenvima	Kinase inhibitor	1,887	8.4%
Kisqali	Kinase inhibitor	1,877	7.6%
Gemcitabine	Nucleoside metabolic inhibitor	1,748	5.3%
Etoposide	Topoisomerase inhibitor	1,719	2.8%
Ipilimumab	CTLA-4-directed blocking antibody	1,674	8.5%
Fluorouracil	Nucleoside metabolic inhibitor	1,643	2.7%
Sandostatin LAR Depot	—	1,637	9.7%
Lynparza	Poly(ADP-Ribose) polymerase inhibitor	1,522	10.6%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.5% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Kinase inhibitor	37,065	4.4%	2.5%
Programmed death Receptor-1 blocking antibody	21,578	9.5%	9.1%
Nucleoside metabolic inhibitor	8,967	2.9%	1.3%
Platinum-based drug	8,830	3.8%	3.9%
Microtubule inhibitor	6,130	4.2%	4.2%
Aromatase inhibitor	6,058	8.6%	8.5%
Androgen receptor inhibitor	5,764	9.3%	7.3%
Alkylating drug	5,239	2.1%	1.8%
Poly(ADP-Ribose) polymerase inhibitor	4,568	8.8%	8.4%
CTLA-4-directed blocking antibody	3,971	8.7%	8.9%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.1%115

2 to 110.7%661

12 to 170.5%504

18 to 446.4%6,438

45 to 6425.2%25,252

65 to 7418.6%18,680

75 and over12.6%12,667

Age not given35.9%35,993

Patient sex

Female44.5%44,627

Male44.7%44,850

Not given10.8%10,833

Grey bar: all 20,646,523 reports in the database. 33.1% of these reports give the United States as the country.

Questions about "Malignant neoplasm progression"

What does "Malignant neoplasm progression" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record malignant neoplasm progression?

100,310 reports through June 2026 (0.5% of all reports), 8,084 of them in the latest 12 months.

Which drugs appear most often in these reports?

Keytruda (8,783), Nivolumab (5,094), Carboplatin (4,906), Opdivo (4,542) and Xtandi (4,434). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.